Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID‐19 patients [PDF]
EMBO Molecular Medicine, 2020 Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID‐19 infection via proposed anti ...
Justin Stebbing +2 more
exaly +4 more sources
Safety profile of baricitinib in patients with systemic lupus erythematosus: an integrated analysis
RMD Open, 2023 Objectives To assess the safety of the oral Janus kinase inhibitor baricitinib in adult patients with systemic lupus erythematosus (SLE) receiving stable background therapy.
Josef S Smolen +10 more
doaj +2 more sources
Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results [PDF]
JEADV Clinical Practice, 2022 Background Baricitinib is the first JAK inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Efficacy and safety were shown in clinical trials, but daily practice data is sparse.
Linde deWijs +4 more
doaj +2 more sources
Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis [PDF]
RMD Open, 2019 Objectives To evaluate radiographic progression of structural joint damage over 2 years in patients with rheumatoid arthritis from baricitinib clinical trials who were disease-modifying antirheumatic drug (DMARD)–naïve or had an inadequate response to ...
Désirée van der Heijde +8 more
doaj +2 more sources
Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis [PDF]
European Journal of Case Reports in Internal Medicine, 2019 Objectives: Baricitinib is an orally active Janus kinase (JAK) inhibitor used in the treatment of moderate to severe rheumatoid arthritis (RA). Materials and methods: Here, we report the case of a 56-year-old Caucasian male diagnosed with RA who ...
Dimitra Koumaki +4 more
doaj +2 more sources
Tofacitinib and Baricitinib in Type 2 Diabetic Patients with Rheumatoid Arthritis [PDF]
MedicinaBackground and Objectives: Recently, a randomized controlled trial suggested a potential benefit of baricitinib in patients with diabetes mellitus, preserving β-cell function. However, the clinical evidence currently available is limited.
Cristina Martinez-Molina +5 more
doaj +3 more sources
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
EBioMedicine, 2015 Background: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA.
Raphaela T. Goldbach-Mansky +2 more
exaly +3 more sources
Budget impact analysis of baricitinib for treatment of alopecia areata: A Saudi hospital perspective
Saudi Pharmaceutical JournalObjectives: To perform a budget impact analysis (BIA) of the adoption of baricitinib for the management of alopecia areata (AA) by a Saudi public sector payer.
A. Alshahrani +6 more
doaj +2 more sources
Off-target profiling of tofacitinib and baricitinib by machine learning: a focus on thrombosis and viral infection. [PDF]
, 2021 Objectives: There are no clear on-target mechanisms that explain the increased risk for thrombosis and viral infection or reactivation associated with Janus kinase (JAK) inhibitors.
Maria Luisa , Faquetti +4 more
core +2 more sources
Baricitinib and tofacitinib off-target profile, with a focus on Alzheimer’s disease [PDF]
, 2023 Introduction: Janus Kinase (JAK) inhibitors were recently identified as promising drug candidates for repurposing in Alzheimer’s disease (AD) due to their capacity to suppress inflammation via modulation of JAK/STAT signalling pathways.
Maria Luisa , Faquetti +8 more
core +2 more sources